NL-OMON29795已完成2 期
Phase II multi-centric, randomised, open-label, parallel-group study to assess the non-inferiority of Pamorelin® 11,25 mg SC injected versus Pamorelin® 11,25 mg IM injected in patients suffering from advanced prostate cancer - Pamoject
Ipsen Pharmaceuticals0 个研究点目标入组 210 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Written informed consent
- •Male patients aged 18 years and older
- •Histological proven prostate cancer, locally advanced or metastatic and scheduled to receive hormonal deprivation therapy.
排除标准
- •Hypersensitivity to Pamorelin or drugs with similar structure.
- •Was treated with other IMP within the last 30 days before study entry.
- •Has previously received a LHRH analogue, estrogens or a steroidal anti-androgen within the last year preceding the study.
- •Patient who underwent orchidectomy or is scheduled to receive an orchidectomy during the course of this study.
研究者
相似试验
进行中（未招募）
1 期
Phase II randomised, open-label, multicentric clinical trial of neoadjuvant treatment comprising chemotherapy and trastuzumab with or without metformin, in women with HER2/ErbB2 positive primary breast cancer.EUCTR2011-000490-30-ESInstitut Català d'Oncologia
进行中（未招募）
不适用
A phase II open-label, multi-centre, randomised, prospective, parallel-group study comparing Topotecan/Carboplatin administered 5 days versus 3 days versus Topotecan monotherapy daily x 5 as second line treatment for patients with relapsed extensive disease small cell lung cancer - Top ChallengeProspective randomized multi-center open label phase II study to determine the antitumoral activity and the feasibility of a combination therapy with Hycamtin/Carboplatin administered 5-days versus 3-days versus Topotecan monotherapy 5-days as second line treatment for patients with histological or cytological verified relapse or progression of extensive disease small cell lung cancer, documented later than 60 days after day 1 of the last cycle of first-line therapy.MedDRA version: 9.1Level: LLTClassification code 10041068Term: Small cell lung cancer extensive stageEUCTR2007-001069-14-DEAktion Bronchialkarzinom e.V.
已完成
2 期
A clinical study to compare safety and efficacy of two brands of buprenorphine (XPRENOR and SUBUTEX) in patients who are opioid dependent.CTRI/2013/06/003782Martindale Pharma54
进行中（未招募）
1 期
A study to test GlaxoSmithKline's (GSK) candidate vaccine-GSK1437173A for prevention of shingles in children with kidney transplant.Herpes Zoster Renal transplant Pediatric populationMedDRA version: 20.1Level: LLTClassification code 10040555Term: ShinglesSystem Organ Class: 100000004862EUCTR2019-000607-33-ITGLAXOSMITHKLINE BIOLOGICALS184
进行中（未招募）
不适用
APG101 in glioblastomaGlioblastoma Multiforme (first or second progression)MedDRA version: 14.1Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-013421-42-DEApogenix GmbH83